MCE products for research use only. We do not sell to patients.

Kojic acid

MCE China：Kojic acid

Brand：MedChemExpress (MCE)

Cat. No.HY-W050154

CAS：501-30-4

Purity：99.99%

Storage：Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month

Shipping：Room temperature in continental US; may vary elsewhere.

Description：Kojic acid is a substance produced by Aspergillus oryzae that is orally effective and can also be absorbed transdermally. Kojic acid exhibits various biological activities, including anti-aging, anti-nematode, antimicrobial, antioxidant, and anti-inflammatory effects. Kojic acid is a Tyrosinase inhibitor with an Mushroom Tyrosinase IC50 of 182.7 μM. Kojic acid prevents melanin production by capturing copper ions that bind to the tyrosinase active site, thus inhibiting its activation. Kojic acid also suppresses the NF-κB and p21 signaling pathways in human keratinocytes. Kojic acid derivatives have anticancer activity.

In Vitro：Kojic acid (1000 μM, 7 days) enhances the cell migration ability of HCEC cells and exhibits anti-aging activity[1]. Kojic acid (1000 μM, 7 days) may alleviate the angiogenesis of human umbilical vein endothelial cells (HUVEC), induced by senescent supernatant of HCEC cells, through NF-κB and p21 signaling pathways[1]. Kojic acid (1.4-1000 μg/mL, 3 days) exhibits dose-dependent mortality and hatch inhibition rates against Meloidogyne incognita, with EC50 values of 195.2 μg/mL and 238.3 μg/mL, respectively[4]. Kojic acid (500 or 1000 µM, 72 h) reduces tyrosinase expression in B16-4A5 and HMV-II cells, indicating that kojic acid inhibits melanogenesis by suppressing tyrosinase activity[6]. Kojic acid (10-2500 μM, 7 days) does not significantly affect the viability of HCEC cells[1].

In Vivo：Kojic acid (50 mg/kg, p.o., once daily for 3 weeks) exhibits antioxidant and anti-inflammatory activities in a mouse model of Alzheimer's disease induced by β-Amyloid (1-42), human (HY-P1363A) [8]. Kojic acid (4, 6.4, 10, 16 g/kg, p.o., single dose) does not exhibit significant toxicity in acute oral studies in JCL-Wistar rats[2].

Hot selling product：BAPTA-AM  | Magrolimab  | L-Ascorbic acid  | Vancomycin  | TVB-3664  | BMS-202  | Irinotecan  | Monalizumab  | Palmitic acid  | SB 204995

Trending products：Recombinant Proteins  |  Bioactive Screening Libraries  |  Natural Products  |  Fluorescent Dye  |  PROTAC  |  Isotope-Labeled Compounds  |  Oligonucleotides

References：

[1]. Wei X, et al. Kojic acid inhibits senescence of human corneal endothelial cells via NF-κB and p21 signaling pathways. Exp Eye Res. 2018 Dec 28;180:174-183.  [Content Brief]

[2]. Burnett C L, et al. Final report of the safety assessment of kojic acid as used in cosmetics[J]. International journal of toxicology, 2010, 29(6_suppl): 244S-273S.  [Content Brief]

[3]. Saeedi M, et al. Kojic acid applications in cosmetic and pharmaceutical preparations. Biomed Pharmacother. 2019 Feb;110:582-593. doi: 10.1016/j.biopha.2018.12.006.  [Content Brief]

[4]. Kim T Y, et al. Nematicidal activity of kojic acid produced by Aspergillus oryzae against Meloidogyne incognita[J]. Journal of Microbiology and Biotechnology, 2016, 26(8): 1383-1391.  [Content Brief]

[5]. Zilles J C, et al. Biological activities and safety data of kojic acid and its derivatives: A review[J]. Experimental dermatology, 2022, 31(10): 1500-1521.  [Content Brief]

[6]. Kai H, et al. Assessment of the effect of arbutin isomers and kojic acid on melanin production, tyrosinase activity, and tyrosinase expression in B16-4A5 and HMV-II melanoma cells[J]. Planta Medica Letters, 2015, 2(01): e39-e41.

[7]. Karakaya G, et al. Synthesis and cytotoxic evaluation of kojic acid derivatives with inhibitory activity on melanogenesis in human melanoma cells[J]. Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry-Anti-Cancer Agents), 2018, 18(15): 2137-2148.  [Content Brief]

[8]. Khan A, et al. Antioxidative and Anti-inflammatory Effects of Kojic Acid in Aβ-Induced Mouse Model of Alzheimer's Disease. Mol Neurobiol. 2021 Oct;58(10):5127-5140.  [Content Brief]